NEWAMSTERDAM PHARMA COMPANY NAMS
ORDINARY SHARES · Common Stock · CUSIP N62509109
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 81.6m as of 2022-12-31, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $10.81.
Biggest buyers
| Frazier Life Sciences Management, L.P. | New | +9.3m |
| Bain Capital Life Sciences Investors, LLC | New | +8.3m |
| RA CAPITAL MANAGEMENT, L.P. | New | +4.0m |
| VIKING GLOBAL INVESTORS LP | New | +3.8m |
| DEERFIELD MANAGEMENT COMPANY, L.P. | New | +2.5m |
| Medicxi Ventures Management (Jersey) Ltd | New | +2.0m |
| BVF INC/IL | New | +1.5m |
| GMT Capital Corp | New | +1.0m |
| JANUS HENDERSON GROUP PLC | New | +563.1k |
| Ensign Peak Advisors, Inc | New | +355.0k |
Biggest sellers
| None |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Capital World Investors 13G · institution +1.7 pts · filed 2026-06-04 | 10.4% |
| RA CAPITAL MANAGEMENT, L.P. 13G · passive investor no change · filed 2025-05-15 | 9.9% |
| FMR LLC 13G · institution +1.2 pts · filed 2026-08-06 | 8.8% |
| Frazier Life Sciences X, L.P. 13D · may seek influence +1.0 pts · filed 2026-09-22 | 8.7% |
| Forbion Capital Fund IV Cooperatief U.A. 13D · may seek influence -1.1 pts · filed 2025-09-30 | 8.3% |
Fell to 5% or below in the last year: BCLS II Investco, LP (1.8%, 2026-05-14), VIKING GLOBAL INVESTORS LP (3.7%, 2026-02-17)
Insider purchases and sales in Q4 2022
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported in Q4 2022.
Holders, Q4 2022
| Manager | Shares | Change |
|---|---|---|
| Frazier Life Sciences Management, L.P. 6.33% of their portfolio | 9.3m $101.8m | New |
| Bain Capital Life Sciences Investors, LLC 10.11% of their portfolio | 8.3m $90.5m | New |
| RA CAPITAL MANAGEMENT, L.P. 0.88% of their portfolio | 4.0m $43.6m | New |
| VIKING GLOBAL INVESTORS LP 0.20% of their portfolio | 3.8m $39.5m | New |
| DEERFIELD MANAGEMENT COMPANY, L.P. 0.56% of their portfolio | 2.5m $27.0m | New |
| Medicxi Ventures Management (Jersey) Ltd 9.16% of their portfolio | 2.0m $21.8m | New |
| BVF INC/IL 0.68% of their portfolio | 1.5m $16.0m | New |
| GMT Capital Corp 0.50% of their portfolio | 1.0m $10.9m | New |
| JANUS HENDERSON GROUP PLC 0.00% of their portfolio | 563.1k $5.3m | New |
| Ensign Peak Advisors, Inc 0.01% of their portfolio | 355.0k $3.9m | New |
| Alyeska Investment Group, L.P. 0.02% of their portfolio | 200.0k $1.9m | New |
| JPMORGAN CHASE & CO 0.00% of their portfolio | 1.1k $12.0k | New |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 88 $1.0k | New |
| DUPONT CAPITAL MANAGEMENT CORP 0.00% of their portfolio | 1 $11 | New |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | New |